MarketBeat
16 May 2026, 02:07 UTC · 24w ago
Verdict
Headline takes no side. We score JNJ −0.20 across six claims — slightly bearish.
−0.20slightly bearish
More negative than 70% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
6 claims · scored −1 bearish … +1 bullish
Stereotaxis reiterated full-year guidance for double-digit revenue growth and total revenue exceeding $40 million, with revenue expected to increase sequentially each quarter.
So whatReaffirmed top-line growth guidance despite a declining Q1 provides a strong positive signal to investors about the expected success of the ongoing commercial transition.
More positive than 99% of claims this week
MAGiC catheter demand is currently much higher than supply, with adoption limited by production capacity rather than market interest.
Continue reading
5 related stories
Search tags
More positive than 98% of claims this week
First-quarter revenue fell 16% year-over-year to $6.3 million due to the ongoing transition away from the legacy Johnson & Johnson catheter ecosystem.
So whatA sharp Q1 revenue decline driven by ecosystem transition highlights immediate execution risk and revenue cannibalization that investors must weigh against future growth promises.
More negative than 98% of claims this week
Initial MAGiC procedures are generating disposable revenue often above $8,000 per procedure, and a single European hospital placed a $100,000 monthly disposable order.
So whatHigh per-procedure revenue and large institutional orders validate the commercial value and pricing power of the new proprietary catheter, supporting the long-term recurring revenue thesis.
More positive than 97% of claims this week
Which stocks this story touches
More negative than 70% of ticker scores this week
The company is seeing a reduction in dependence and a transition away from its ecosystem by Stereotaxis.
More positive than 53% of ticker scores this week
Despite current revenue declines and losses, the company has strong future tailwinds from new FDA approvals, a proprietary catheter, and positive full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
23h ago
[mutual] Stereotaxis has an exclusive collaboration with MicroPort to sell an additional catheter in Europe.
+18.5%
Price is moving against the score
$268.54 vs $226.71 close before publication (May 15) · not market-adjusted
JNJ chart →
